曲罗芦单抗治疗中重度特应性皮炎长达4.5年安全性分析
该研究整合7项安慰剂对照试验与开放扩展研究ECZTEND,评估曲罗芦单抗在成人及青少年中重度特应性皮炎中的长期安全性。2693例患者接受治疗长达238.5周(约4.5年,PYE=5320.2),不良事件多为轻中度,未见新安全性信号,长期耐受性良好。
要点
- 曲罗芦单抗长期治疗中重度AD耐受性良好,未发现新安全性信号。
- 鼻咽炎、结膜炎和注射部位反应发生率高于安慰剂,但多为轻中度。
- 需全身治疗的皮肤感染和疱疹性湿疹发生率低于安慰剂。
核心结论
- 曲罗芦单抗在成人及青少年中重度AD中长期使用耐受性良好,与初始安慰剂对照期一致,未发现新安全性信号。
研究设计与样本
- 整合7项安慰剂对照试验和正在进行的开放扩展研究ECZTEND(NCT03587805)的安全性分析。
- 分析两个安全性集:初始16周安慰剂对照安全性集和全部曲罗芦单抗安全性集(数据截止2022年4月30日)。
- 全部曲罗芦单抗安全性集共2693例患者,接受治疗长达238.5周(约4.5年,PYE=5320.2)。
- 计算发生事件的患者比例和每100患者年暴露的发病率(IR),PYE定义为至首次事件或暴露结束的时间。
主要发现
- 两个安全性集的安全性结果相似,大多数不良事件为非严重、轻中度。
- 曲罗芦单抗vs安慰剂发生率更高的常见不良事件:鼻咽炎(IRR 1.26)、结膜炎(IRR 3.11)、注射部位反应(IRR 19.57)。
- 曲罗芦单抗vs安慰剂发生率更低:特应性皮炎(IRR 0.51)和哮喘(IRR 0.57)。
- 特别关注的不良事件中,眼部疾病在曲罗芦单抗组发生率更高(IRR 2.43),其中98%为轻中度。
- 需全身治疗的皮肤感染(IRR 0.43)和疱疹性湿疹(IRR 0.32)在曲罗芦单抗组更少。
关键数值与推荐
- 鼻咽炎IRR 1.26,结膜炎IRR 3.11,注射部位反应IRR 19.57(曲罗芦单抗vs安慰剂)。
- 特应性皮炎IRR 0.51,哮喘IRR 0.57(曲罗芦单抗vs安慰剂)。
- 眼部疾病AESI的IRR 2.43,98%为轻中度。
- 需全身治疗的皮肤感染IRR 0.43,疱疹性湿疹IRR 0.32。
临床怎么用
- 长期使用曲罗芦单抗时,应关注鼻咽炎、结膜炎和注射部位反应,但多数为轻中度。
- 需全身治疗的皮肤感染和疱疹性湿疹发生率较低,长期治疗中无需过度担忧。
- 眼部不良事件虽发生率较高,但98%为轻中度,可进行常规监测。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Patients with moderate-to-severe atopic dermatitis (AD) require long-term management. Understanding the long-term safety of new treatments is a top priority for patients and healthcare professionals. OBJECTIVES: To evaluate the safety of tralokinumab in adults and adolescents with moderate-to-severe AD by conducting an integrated safety analysis of seven placebo-controlled trials and the ongoing, open-label extension study ECZTEND (NCT03587805). METHODS: An initial 16-week placebo-controlled (PBO-CTRL) safety set and an all-tralokinumab (ALL-TRALO) safety set combining the placebo-controlled trials and ECZTEND (data cutoff 30 April 2022) were analysed. All treatment-emergent adverse events were recorded. Adverse events of special interest (AESIs) were predefined. Safety areas of clinical interest for advanced systemic AD treatments were captured retrospectively. Proportions of patients with events and incidence rates (IRs) per 100 patient-years of exposure (PYE) were calculated. PYE was defined as the time until the first event or exposure end, whichever came first, and incidence was defined as the first event. RESULTS: Safety results were similar between the PBO-CTRL safety set and ALL-TRALO safety set. In the latter, 2693 patients received tralokinumab for up to 238.5 weeks (approximately 4.5 years, PYE = 5320.2). Most adverse events (AEs) were nonserious, mild or moderate in severity, and occurred with similar frequencies between tralokinumab and placebo in the PBO-CTRL safety set. The most common AEs that occurred at higher rates for tralokinumab vs. placebo were nasopharyngitis [IR ratio (IRR) comparing tralokinumab vs. placebo 1.26], conjunctivitis (IRR 3.11) and injection site reaction (IRR 19.57). Dermatitis atopic and asthma occurred at lower rates with tralokinumab vs. placebo (IRR 0.51 and IRR 0.57, respectively). AESI eye disorders occurred at higher rates with tralokinumab vs. placebo (IRR 2.43) and 98% were mild to moderate. AESIs that were less frequent with tralokinumab vs. placebo included skin infections requiring systemic treatment (IRR 0.43) and eczema herpeticum (IRR 0.32). Rates of AEs of clinical interest (related to other approved systemic AD treatments) were low and similar between treatment groups. IRs of AEs did not increase with longer exposure in the ALL-TRALO safety set. CONCLUSIONS: Long-term use of tralokinumab in adults and adolescents with moderate-to-severe AD was well-tolerated and consistent with the initial placebo-controlled treatment period, with no new safety signals identified. Atopic dermatitis is a skin disease caused by an overactive immune system. It leads to recurring, itchy and dry patches of skin. It is also known as eczema. The disease is estimated to affect over 200 million people worldwide. It often requires long-term treatment and can have an impact on a person’s quality of life. Tralokinumab is a medicine that is injected under the skin. It is approved in many countries to treat patients over 12 years of age with moderate-to-severe atopic dermatitis. In this study, we examined the side effects of tralokinumab treatment in 2693 patients with atopic dermatitis treated for up to four and a half years. Our results were similar to other studies of tralokinumab. No new side effects were identified. Most side effects were mild or moderate. Common side effects with tralokinumab treatment included the common cold, conjunctivitis (‘pink eye’) and skin reactions where the medicine was injected. We also looked at side effects linked to other long-term treatments for AD. These included infections, joint stiffness and nausea. We found that the rates of these side effects while taking tralokinumab were low and did not increase over time. In conclusion, our findings suggest that long-term treatment with tralokinumab can be well-tolerated by patients for up to four and half years. This supports the strong safety profile of tralokinumab for patients with moderate-to-severe AD.
引用
- Reich K, Langley RG, Silvestre Salvador JF, et al. Safety of tralokinumab in patients with moderate-to-severe atopic dermatitis followed for up to 4.5 years: an integrated analysis of eight clinical trials. Br J Dermatol. 2026. PMID: 40879371. doi:10.1093/bjd/ljaf309
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。